#USA #diagnostics #Werfen #Bedford

Werfen Expands its Hemostasis and Acute Care Diagnostics Technology Center in Bedford, Massachusetts

Werfen, a renowned name in specialized diagnostics, has recently made headlines with the official announcement of a new building at its Hemostasis and Acute Care Diagnostics Technology Center located in Bedford, Massachusetts. This strategic expansion signifies a robust commitment to innovation in healthcare technology and research, further enhancing its capabilities to develop advanced diagnostic solutions.

The unveiling of this new facility is accompanied by a significant investment exceeding $50 million, which will lead to an impressive 105,000 additional square feet of space dedicated to research and development. This expansion will not only accommodate the company's growing workforce but also bolster its innovation programs. Werfen's Chairman, Marc Rubiralta, along with top executives, participated in a ribbon-cutting ceremony to celebrate this milestone.

Originally established in 2009, Werfen's Technology Center in Bedford started with a workforce of 600 employees. Fast forward to today, the number has more than doubled to over 1,200, reflecting the company's success and increasing demand for its specialized diagnostic products. With the new building, Werfen predicts it can support up to 2,000 employees, setting the stage for future growth and innovation.

Giovanni Russi, the Chief Operating Officer of Hemostasis and Acute Care Diagnostics, highlighted the importance of Massachusetts as a hub for healthcare innovation, stating, "Our expanded Technology Center represents the commitment of our shareholders and the Company to the Commonwealth of Massachusetts, as the optimal hub for healthcare innovation."

Bedford, strategically located near Boston, stands out as an ideal location for these expansions due to its proximity to top-notch academic institutions and research centers. This region is home to some of the finest research scientists, fostering an environment that is conducive to cutting-edge medical advancements.

Werfen's focus on specialized diagnostics spans several critical clinical areas, including Hemostasis, Acute Care, Transfusion, Autoimmunity, and Transplant. Their diagnostic solutions have been pivotal in supporting clinicians and enhancing patient care globally. Today, Werfen employs over 7,000 individuals, with approximately 55% of its workforce based in the United States and a notable 15% in Bedford alone.

The company is recognized for producing a variety of specialized diagnostic instruments and related reagents designed primarily for use in hospitals and clinical laboratories. These include advanced systems like the GEM Premier series and the ACL TOP family of Hemostasis testing systems. Their innovative technology ensures the delivery of high-quality diagnostic results, contributing significantly to patient management and treatment.

Through this expansion, Werfen demonstrates a profound commitment to improving healthcare outcomes by investing in state-of-the-art technology and expanding its specialized diagnostics capabilities. As healthcare needs continue to evolve, Werfen's strategic growth aligns perfectly with the industry's demands, ensuring that patients receive the most accurate and timely diagnostic care possible.

In summary, Werfen's latest expansion of its Bedford technology center is not just a growth milestone for the company, but rather a significant step forward in healthcare innovation. With more investments expected in the future, Werfen is poised to remain a leader in the world of specialized diagnostics, continuously enhancing patient care through innovative solutions.